| Document |
Document Title |
|
WO/2016/107331A1 |
A new crystal form of a Cefathiamidine compound and a preparation method therefor. The method comprises: dissolving a Cefathiamidine compound with the purity greater than or equal to 98% in a solvent selected from methanol and the like t...
|
|
WO/2016/095660A1 |
A new crystal form of cefamandole sodium compound and preparation method thereof, the method comprising: adding cefamandole sodium solid to an organic solvent to prepare a 0.04-0.3 g/ml suspension, stirring and suspending for a period of...
|
|
WO/2016/088041A1 |
The present invention relates to a stable extended-release composition of cefpodoxime proxetil and a process for its preparation. The composition comprises cefpodoxime proxetil, a stabilizer, and a release-controlling agent, wherein the ...
|
|
WO/2016/065525A1 |
Disclosed is a use of oxopiperazinyl amide compounds as shown by formula I, and isomers, hydrates or salts thereof in the preparation of drugs for inhibiting PLK1 activity.
|
|
WO/2016/046055A1 |
The present invention relates to the hemi sulfuric acid salt of D-phenylglycine methyl ester, to a method for the preparation of said salt and to the use of said salt in the enzymatic synthesis of antibiotics and of D-phenylglycine methy...
|
|
WO/2016/035845A1 |
The present invention provides an acid addition salt or sodium salt of a compound represented by formula (IA), a hydrate of the salt or a stable crystalline solid form of the salt. The salt or the crystalline solid form thereof is extrem...
|
|
WO/2016/035847A1 |
The present intention provides compounds represented by formula (IV) (in the formula, R1 is a protecting group of an amino group, and R2 and R3 are each independently a protecting group of a carboxy group), pharmaceutically acceptable sa...
|
|
WO/2016/027262A1 |
A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderop...
|
|
WO/2016/025813A1 |
Described herein are crystalline forms of a compound of formula (ΙΙΓ), including toluene solvates ofT A TD-CLE, as well as processes for the preparation thereof and use thereof in the preparation of cephalosporin compounds such as cef...
|
|
WO/2016/025839A1 |
Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction. Provided herein are methods for the synthesis of cephalosporin compounds of formula (I) employing a p...
|
|
WO/2016/004166A1 |
Boron-based prodrugs of phenol- or aromatic hydroxyl group -containing therapeutic molecules ("original drugs"), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged r...
|
|
WO/2015/119962A1 |
Beta-Lactamase substrates and methods for using the substrates to detect beta-lactamase and to diagnose tuberculosis. In the method, a sample is contacted with a compound of the invention, and an optical signal generated from contacting ...
|
|
WO/2015/109056A1 |
The present invention discloses a probe useful for the selective detection of metallo-beta-lactamases, in particular carbapenemases, thereby distinguishing those species of bacteria that are carbapenem-resistant from bacterial strains th...
|
|
WO/2015/021692A1 |
Provided is a bacteria culture medium, wherein the culture medium is prepared by adding one or more β-lactam antibiotics and/or salts thereof to an ordinary bacteria culture medium in advance, wherein the β-lactam antibiotics and/or sa...
|
|
WO/2014/189308A1 |
The present invention relates to: a novel crystal form of cefditoren pivoxil readily convertible into an amorphous form, to be used as an active ingredient of a drug, and having high cefditoren pivoxil purity; and a preparation method th...
|
|
WO/2014/168105A1 |
A compound represented by formula (I) (In the formula, W is -CH2-, etc., U is -S-, etc., R1 is a substituted or unsubstituted carbocyclic group, etc., R2A and R2B together form an oxo, a substituted or unsubstituted methylidyne or a subs...
|
|
WO/2014/165126A2 |
Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive...
|
|
WO/2014/158952A1 |
The present invention relates to a compound of formula I wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; a...
|
|
WO/2014/152763A1 |
Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.
|
|
WO/2014/128538A1 |
The invention relates to an in-situ process for the preparation of amoxicillin trihydrate from sugarcane juice without isolation of the intermediates produced during the reaction sequence viz penicillin G and 6-aminopenicillanic acid. Th...
|
|
WO/2014/104148A1 |
A compound represented by formula (I) (in the formula, W is -CH2- or the like, U is -S- or the like, R1 is a substituted or unsubstituted carbocyclic group or the like, R2A and R2B are a) or b) described in the description, R3 is a hydro...
|
|
WO/2014/068388A1 |
The compounds of formula (I) of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram nega...
|
|
WO/2014/069649A1 |
The invention relates to processes for the production of intermediates for preparing 2-alkyl cephem compounds useful as antimicrobial drugs. The invention provides a process which comprises oxidating a compound of the formula (I) or a sa...
|
|
WO/2014/040239A1 |
Disclosed is a cefuroxime sodium crystal compound and a composition powder injection thereof, wherein the crystal form of cefuroxime sodium is amorphous and the preparation method thereof is as follows: reacting cefuroxime acid with sodi...
|
|
WO/2014/026143A1 |
Disclosed herein are synthesis methods for generation of conjugated anti-microbial compounds and conjugated anti-cancer compounds. Several embodiments, related to the uses of such compounds in the treatment of infections, in particular t...
|
|
WO/2014/012849A1 |
The present invention relates to a new crystal form of cefoperazone sodium and the method for making said crystal form. The new crystal form has the following characteristics: orthorhombic crystal, space group F222, unit cell dimensions ...
|
|
WO/2013/173519A1 |
β-Lactamase substrates and methods for using the substrates to detect β-lactamase diagnose tuberculosis.
|
|
WO/2013/114319A1 |
The present invention concerns a direct process, without the need to isolate any intermediate, for the preparation of Cefepime dihydrochloride monohydrate of sterile quality (for injective use) comprising a preliminary decolorization ste...
|
|
WO/2013/109927A2 |
It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide ("AMP") and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain...
|
|
WO/2013/084171A1 |
The present invention relates to a process for the preparation of ceftaroline salts or hydrates thereof.
|
|
WO/2013/057197A1 |
The present invention relates to a process for the preparation of O-formyl cefamandole, an intermediate in the preparation of cefamandole nafate, by formylation of cefamandole.
|
|
WO/2013/057196A1 |
The present invention relates to a process for the preparation of cefamandole nafate from cefamandole and to the use thereof in the manufacture of a medicament for treatment of a bacterial disease.
|
|
WO/2013/051597A1 |
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, A represents a group represented by one of formulae (i)-(iii); B represents a group represented by formula (v) or (vi); and E represent...
|
|
WO/2013/041999A1 |
The present invention relates to an improved process for the preparation of cefpodoxime acid from 7-Amino cephalosporanic acid. Further the preparation of cefpodoxime proxetil from cefpodoxime acid is also described.
|
|
WO/2013/034718A1 |
The present invention relates to a novel process for preparing ceftaroline fosamil as well as to a intermediates of formulae (1), (3) or (4) of this process.
|
|
WO/2013/010296A1 |
A method for purifying cefmenoxime hydrochloride, comprising specifically the following steps: 1) adding a cefmenoxime hydrochloride-insoluble solvent to a cefmenoxime hydrochloride raw material, removing impurities by filtering; 2) usin...
|
|
WO/2013/010297A1 |
A method for purifying ceftizoxime sodium, comprising (1) dissolving crude ceftizoxime sodium in water, extracting with cyclohexane or ethyl acetate, and acquiring an aqueous phase having ceftizoxime sodium; (2) introducing ammonia or am...
|
|
WO/2013/002215A1 |
The present invention provides a novel compound which has a broad antibacterial spectrum and particularly exhibits a high antibacterial activity on β-lactamase-producing gram-negative bacteria. Specifically provided are: a compound repr...
|
|
WO/2012/175587A2 |
The present invention relates to a crystalline form of an intermediate for cefoperazone of formula (1 ) and to a process for the preparation thereof by enzymatic condensation of a 3'-thiosubstituted β-lactam nucleus with a phenylglycine...
|
|
WO/2012/155203A1 |
Regulation of nitric oxide release and biofilm development Abstract The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate...
|
|
WO/2012/150520A1 |
The present invention provides novel cephalosporin derivatives of formula (I), their analogues, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the prepar...
|
|
WO/2012/147773A1 |
The present invention provides a novel compound having a wide antibacterial spectrum, and expressing strong antibacterial activity against beta-lactamase-producing gram-negative bacteria in particular. This invention provides the compoun...
|
|
WO/2012/134184A2 |
The present invention relates to a novel cephalosporin derivative indicated in chemical formula 1 of the description. In the chemical formula 1, X, Y, L, R1, R2 are identical as defined in the detailed explanation. In addition, the prese...
|
|
WO/2012/126148A1 |
A method for purifying cefotiam hydrochloride is provided, which comprises the following steps: step 1) dissolving raw material cefotiam hydrochloride in water, treating the solution with an acidic salt, then decreasing the temperature a...
|
|
WO/2012/126147A1 |
Disclosed herein is a purification method of cefmetazole sodium including processing steps as follows: step 1), dissolve the raw material cefmetazole sodium into water, and extract it by adding water insoluble organic solvent, then disca...
|
|
WO/2012/117038A1 |
The present invention relates to the degradation of β-lactam compounds such as penicillins in the presence of other β-lactam compounds such as cephalosporins. Furthermore the present invention relates to the use of sulfite in the degra...
|
|
WO/2012/100383A1 |
Provide a process of refining cefamandole sodium comprising steps as follows: step 1), adsorbing cefamandole sodium by strong acid ion exchange resin, and collecting the eluant after eluting, then decompressing and concentrating to obtai...
|
|
WO/2012/049576A1 |
The present invention relates to a novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of a novel polymorph of crystalline Ceftiofur sodium of formula (I).
|
|
WO/2012/032040A1 |
The present invention relates to a composition comprising ≥85 wt% of an N-deacylated cephalosporin, a process for making the same and the use of said N-deacylated cephalosporin in the preparation of highly pure semi synthetic cephalosp...
|
|
WO/2011/144021A1 |
A cefpiramide sodium hydrate, preparation method and uses thereof are disclosed. The cefpiramide sodium hydrate has better storage stability, and is applicable to produce medicaments for treating or preventing human or animals diseases o...
|
